Warngau, Germany, July 24, 2025

AMW GmbH, a specialty pharmaceutical company focused on biodegradable controlled-release drug delivery systems, today announced the closing of a significant financing agreement. This long-term and attractive financing from Raiffeisenlandesbank Oberösterreich allowed the Company to optimize its financing structure and to gain access to an additional line of credit.

“With another record result for the 2024 financial year, based on a significant increase in revenues of 30%, we managed to reposition a considerable portion of our financing structure from a position of strength,” said Matthias Dittmer, Vice President Finance and IT at AMW. “The Company’s positive assessment from the financial markets is reflected in this successful growth financing. This underlines the confidence our financial partners hold in the stability and future viability of AMW. We are delighted to have entered bank financing with Raiffeisenlandesbank Oberösterreich.”

“The new financing agreement is an important milestone for AMW, enabling us to pursue our strategic goals with even greater stability and flexibility,” added Philipp Karbach, CEO and shareholder of AMW. “I would like to express my sincere thanks to all partners and colleagues involved in this project.”

AMW will use the additional liquid funds deriving from the refinancing to further pursue on its sustainable growth trajectory with a focus on its core business of developing, manufacturing and distribution of biodegradable controlled-release drug delivery systems. With two approved products on the market, AMW already provides patients in over 45 countries with drug delivery systems for improved adherence and cost-effective therapies.